Research programme: EGFR degrading bispecific antibodies - EpiBiologics
Latest Information Update: 09 May 2024
At a glance
- Originator EpiBiologics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action ErbB receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer